Table 2.
Autoimmune disorders (AD) symptoms and management at baseline
| Characteristic | RCC (n=58) N (%) |
UC (n=48) N (%) |
Overall (n=106) N (%) |
| AD symptoms | |||
| Asymptomatic | 41 (71) | 30 (63) | 71 (67) |
| Symptomatic | 17 (29) | 18 (38) | 35 (33) |
| Severity of baseline AD symptoms* | |||
| Grade 0 (asymptomatic) | 41 (71) | 30 (63) | 71 (67) |
| Grade 1 | 13 (22) | 13 (27) | 26 (25) |
| Grade 2 | 3 (5) | 3 (6) | 6 (6) |
| Grade 3–4 | 0 (0) | 0 (0) | 0 (0) |
| Unknown | 1 (2) | 2 (4) | 3 (3) |
| Concurrent AD treatment at CPI initiation | |||
| Topical corticosteroids | 1 (2) | 2 (4) | 3 (3) |
| Systemic corticosteroids | 2 (3) | 3 (6) | 5 (5) |
| Immunomodulatory agents† | 4 (7) | 1 (2) | 5 (5) |
*Only the worst grade for the same symptom is captured.
†Five patients received one of the following treatments: hydroxychloroquine (rheumatoid arthritis), mesalamine (ulcerative colitis), sulfasalazine (ulcerative colitis), teriflunomide (multiple sclerosis) and methotrexate (psoriatic arthritis).
CPI, checkpoint inhibitor; RCC, renal cell carcinoma; UC, urothelial carcinoma.